Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C2H3O2.Mn |
Molecular Weight | 173.0261 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mn++].CC([O-])=O.CC([O-])=O
InChI
InChIKey=UOGMEBQRZBEZQT-UHFFFAOYSA-L
InChI=1S/2C2H4O2.Mn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
Molecular Formula | C2H3O2 |
Molecular Weight | 59.044 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mn |
Molecular Weight | 54.938 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.alfa.com/en/catalog/032808/https://www.ncbi.nlm.nih.gov/pubmed/6658791https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://google.com/patents/CN104529454A?http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jhttps://www.drugs.com/pro/manganese-sulfate-injection.htmlhttp://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367Curator's Comment: description was created based on several sources, including
https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm
Sources: https://www.alfa.com/en/catalog/032808/https://www.ncbi.nlm.nih.gov/pubmed/6658791https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://google.com/patents/CN104529454A?http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jhttps://www.drugs.com/pro/manganese-sulfate-injection.htmlhttp://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367
Curator's Comment: description was created based on several sources, including
https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm
Manganese citrate is generally recognized as safe direct food additive. Manganese citrate complex has being used in the determination of liver enzyme activities in the aging process and following treatment with aminoethylisothiuronium bromide hydrobromide (AET).
Originator
Sources: https://www.americanelements.com/manganese-ii-iodide-7790-33-2https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19610920&CC=GB&NR=877677A&KC=Ahttp://www.newworldencyclopedia.org/entry/Manganese
Curator's Comment: Manganese was first discovered by Torbern Olof Bergman in 1770 and first isolated by Johann Gottlieb Gahn in 1774.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075097 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19032027 |
|||
Target ID: CHEMBL1795148 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25974698 |
|||
Target ID: CHEMBL4612 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25974698 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseManganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese. |
|||
Primary | Unknown Approved UseManganese is used for weak bones (osteoporosis). |
|||
Palliative | Unknown Approved UseEarly research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension. |
|||
Curative | MANGANESE SULFATE Approved UseManganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
|||
Primary | MANGANESE SULFATE Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Cytochrome oxidase determination using a manganese citrate complex. | 1970 |
|
Metabolism of l-Tyrosine to 4-Hydroxybenzaldehyde and 3-Bromo-4-Hydroxybenzaldehyde by Chloroplast-containing Fractions of Odonthalia floccosa (Esp.) Falk. | 1979 Dec |
|
Effect of fluoride on copper, manganese and zinc in bone and kidney. | 1981 Mar |
|
Effect of quantity and route of administration of manganese monoxide on feed intake and serum manganese in ruminants. | 1985 Feb |
|
Dietary calcium and manganese effects on menstrual cycle symptoms. | 1993 May |
|
Manganese: brain transport and emerging research needs. | 2000 Jun |
|
Equilibrium and kinetics studies of reactions of manganese acetate, cobalt acetate, and bromide salts in acetic acid solutions. | 2001 Jun 18 |
|
Differential ability of transition metals to induce pulmonary inflammation. | 2001 Nov 15 |
|
Is the axial zero-field splitting parameter of tetragonally elongated high-spin manganese(III) complexes always negative? | 2002 Jul 31 |
|
Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate. | 2002 Sep |
|
Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin. | 2003 Jan |
|
Bi- and poly-metallic cyanide-bridged complexes of the redox-active cyanomanganese nitrosyl unit [Mn(CN)(PR3)(NO)(eta-C5H4Me)]. | 2004 Feb 21 |
|
Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. | 2005 Mar |
|
CsR(R(6)CoI(12))2 (R = Gd, Er) and (CeI)0.26(Ce(6)MnI(9))2: two new structure types featuring R(6)Z clusters. | 2006 Nov 27 |
|
Intramolecular Aminoalkoxylation of Unfunctionalized Olefins via Intramolecular Iodoamination and Aziridinium Ion Ring-Opening Sequence. | 2017 Apr 7 |
Patents
Sample Use Guides
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:39 UTC 2023
by
admin
on
Fri Dec 15 15:13:39 UTC 2023
|
Record UNII |
0V6E9Q2I0Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5734
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
C87338
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
211-334-3
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
DTXSID5027279
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
0V6E9Q2I0Y
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
12525
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
MANGANESE(II) ACETATE
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
638-38-0
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
m7059
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | Merck Index | ||
|
C1505
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
CONCEPT | Dietary Supplement | ||
|
300000004000
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
0V6E9Q2I0Y
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | |||
|
1370629
Created by
admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |